Spectrum Pharmaceuticals Inc

Spectrum Pharmaceuticals — Investor Presentation (February 2011)

26 slides from Spectrum Pharmaceuticals's investor presentation, Feb 15, 2011

  1. Slide 1: Company Presentation February 2011

    Rajesh C. Shrotriya, MDChairman, Chief Executive Officer, and President Company Presentation February, 2011

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statem

  3. Slide 3: Clearly Defined Vision and Strategy

    Clearly Defined Vision and Strategy VisionCreating a leading Oncology Biopharmaceutical Company with Development and Commercial abilitiesStrategy Acquire or in-license marketed or late stage development products thereby mitigating risk and reducing time to marketSpectrum has no drug discovery

  4. Slide 4: Focus on Building Value

    Focus on Building Value Value DriversTwo FDA approved, proprietary oncology drugs with increasing revenue and label expansion potentialTwo drugs in Pivotal Trials; NDAs expected to be filed within 24 monthsSignificant pipeline with unique product profileDeveloping single-dose treatments with lasting

  5. Slide 5: Oncology Focused

    Oncology Focused (CHART) Lymphoma Colorectal Bladder Other ZEVALINBelinostat FUSILEV Apaziquone ProstateAdjuvantSolid TumorsBiosimilar Rituximab

  6. Slide 6: Clearly Defined Vision, Strategy and Focus on Building Value

    Clearly Defined Vision, Strategy and Focus on Building Value Well CapitalizedCash & Investments (as of 09/30/10) $92.5MNo Long-Term Debt Diversified Revenue SourcesProduct RevenueAlliance MilestonesMinimal Operating Cash Requirements

  7. Slide 7: Product Sales ($M)

    Product Sales ($M) 2007 2008 2009 2010 (E) 2011 (E) $7.7 $28 Spectrum Growth $0 Trend Line

  8. Slide 8: ZEVALIN Radioimmunotherapy: What is ZEVALIN?

    ZEVALIN Radioimmunotherapy What is ZEVALIN?Anti-CD20 Monoclonal Antibody with Y-90 for Non-Hodgkin's Lymphoma Monoclonal Antibody Radioisotope (Y-90)

  9. Slide 9: ZEVALIN Radioimmunotherapy: What is ZEVALIN?

    ZEVALIN Radioimmunotherapy What is ZEVALIN?Anti-CD20 Monoclonal Antibody with Y-90 for Non-Hodgkin's Lymphoma

  10. Slide 10: ZEVALIN Radioimmunotherapy: What is ZEVALIN?

    Single therapeutic dose with long-term efficacyCategory 1 in NCCN treatment guideline and compendiaFully reimbursedBioScan label removal submitted to FDA ZEVALIN Radioimmunotherapy What is ZEVALIN?"ZEVALIN is in my opinion the most effective single drug available with an acceptable hematological tox

  11. Slide 11: 2010 American Society for Hematology Meeting Papers on ZEVALIN

    2010 American Society for Hematology Meeting (ASH) 12 Papers on ZEVALIN6 Oral PresentationsFeatured Update on FIT Data ZEVALIN Control P-value (Months) (Months) Median Progression-Free Survival (PFS) in all patients randomized 49 14 <0.001 Time to Next Treatment/Time without need for further treatme

  12. Slide 12: What are the Physicians saying about ZEVALIN?

    What are the Physicians saying about ZEVALIN? Dr. Lawrence PiroPresident & CEOThe Angeles Clinic and Research Center

  13. Slide 13: ZEVALIN Sales

    ZEVALIN Sales (CHART) 2009 2010 (E) $15.7 M Guidance$27 - $29 M

  14. Slide 14: FUSILEV (Levoleucovorin): What is FUSILEV?

    FUSILEV is a folate analog approved for:FUSILEV rescue is indicated after high-dose methotrexate therapy in osteosarcoma.FUSILEV is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists Colorect

  15. Slide 15: FUSILEV (Levoleucovorin) Sales

    FUSILEV(r) (Levoleucovorin) Sales (CHART) 2008 2010 (E) 2009 $7.7 M $12.5 M (E)

  16. Slide 16: Colorectal Market Opportunity

    Colorectal Market Opportunity Ex-US sales of levoleucovorin are estimated to be approximately $180 Million(95% for colorectal cancer) FUSILEV is currently not approved for colorectal cancer

  17. Slide 17: Belinostat: Novel HDAC Inhibitor

    HDAC InhibitorProven class of compounds Belinostat Novel HDAC Inhibitor: Potential Backbone in Cancer Therapy Clinical data spans over 700 patients across hematologic malignancies & solid tumors

  18. Slide 18: Belinostat Pivotal Trial in PTCL

    Belinostat Pivotal Trial in PTCL Commercial OpportunityPTCL is an aggressive non-Hodgkin's lymphoma (NHL) with poor clinical prognosis1~7500 new patients per year1, high relapse rateExisting treatment is in excess of $100,000 patient/yearStrong patent positionOrphan drug exclusivitySource: Savage KJ

  19. Slide 19: Belinostat Competitive Profile

    Belinostat Competitive Profile Potential Safety Advantages and Comparable Efficacy to Current Therapies Current Therapies Current Therapies Current Therapies * - Treatment related** - Irrespective of relationship Data not from direct comparison study Peripheral T-Cell Lymphoma (PTCL) Belinostat1SPPI

  20. Slide 20: Belinostat Current & Future Development

    Phase 2 Trial: CUP (Carcinoma of Unknown Primary)Large market opportunity with no approved therapies2-4% of all cancers are CUP*10% of all cancer deaths are CUP*Combination therapy with carboplatin+paclitaxel (standard of care)Unique ability to administer Belinostat via IV and oral dosingAdditional

  21. Slide 21: Apaziquone Pivotal Trial for Bladder Cancer

    Apaziquone Pivotal Trial for Bladder Cancer A Novel DrugNDA Strategy (Under SPA)Two pivotal trials underway: 1,600 patient enrollment completedTop-line results expected in 2012Commercial OpportunitySignificant unmet medical needThe most expensive cancer to treat on a per patient basis

  22. Slide 22: Apaziquone - Phase 3 Non-Muscle Invasive Bladder Cancer

    Papillary Urothelial Carcinoma TUR Surgery Apaziquone - Phase 3 Non-Muscle Invasive Bladder Cancer

  23. Slide 23: Apaziquone Development and Commercialization Partnerships

    Apaziquone Development and Commercialization Partnerships Allergan (2008) $41.5M upfront, $304M milestone payments, plus royaltiesCo-promotion rights in the US Nippon Kayaku (2009)Japan + Asian territories$15M upfront, $136M milestone payments, plus royalties Handok Pharmaceuticals (2009)South Korea

  24. Slide 24: Spectrum Key Milestones: 2011 and Beyond

    Spectrum Key Milestones: 2011 and Beyond ZEVALIN(r)Continue to achieve sales growthGuidance: $27M - $29M in 2010 SalesData submitted to the FDA supporting removal of BioScan requirementDeveloping clinical trial strategies for large B-Cell Lymphoma, a much bigger market potential for ZEVALINIncrease

  25. Slide 25: Near Term Value Drivers

    Near Term Value Drivers Spectrum Pharmaceuticals (NASDAQ: SPPI) FDA Approved/Marketed Belinostat(tm) In pivotal trial FDA Approved/Marketed

  26. Slide 26: Thank You!

    Thank You!

Spectrum Pharmaceuticals — Investor Presentation (February 2011) on 6ix